Extended lymphadenectomy in the surgery of pancreatic adenocarcinoma and its relation to quality improvement issues

Journal of Surgical Oncology

Volumn 99, Issue 4, 2009, Pages 207-214

  Rupp, Christopher C ^a   Linehan, David C ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Pancreaticoduodenectomy; Quality improvement; RAMPS

Indexed keywords

CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HUMAN; LYMPH NODE; LYMPH NODE DISSECTION; LYMPHADENECTOMY; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ADENOCARCINOMA; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; PANCREATIC NEOPLASMS; PANCREATICODUODENECTOMY; QUALITY ASSURANCE, HEALTH CARE;

EID: 62749137443     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21210     Document Type: Review

References (80)

1. American Cancer Society, Cancer Facts and Figures. http://www.cancer.org/ docroot/stt/stt-0.asp. 2007.
2. Sener SF, Fremgen A, Menck HR, et al.: Pancreatic cancer: A report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg 1999;189:1-7.
3. Bramhall SR, Allum WH, Jones AG, et al.: Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: An epidemiological study. Br J Surg 1995;82:111-115.
4. Cameron JL, Riall TS, Coleman J, et al.: One thousand consecutive pancreaticoduodenectomies. Ann Surg 2006;244:10-15.
5. Neoptolemos JP, Stocken DD, Dunn JA, et al.: Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg 2001;234:758-768.
6. Riall TS, Cameron JL, Lillemoe KD, et al.: Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma. Part 3. Update on 5-year survival. J Gastrointest Surg 2005;9:1191-1204; discussion 1204-1196.
7. Farnell MB, Pearson RK, Sarr MG, et al.: A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. Surgery 2005;138:618-628; discussion 628-630.
8. Brennan MF, Kattan MW, Klimstra D, et al.: Prognostic nomogram for patients undergoing resection for adenocarcinoma of the pancreas. Ann Surg 2004;240:293-298.
9. Picozzi VJ, Pisters PW, Vickers SM, et al.: Strength of the evidence: Adjuvant therapy for resected pancreatic cancer. J Gastrointest Surg 2007.
10. Imamura M, Doi R, Imaizumi T, et al.: A randomized multicenter trial comparing resection and radiochemotherapy for resectable locally invasive pancreatic cancer. Surgery 2004;136:1003-1011.
11. Lygidakis NJ, Singh G, Bardaxoglou E, et al.: Mono-bloc total spleno-pancreaticoduodenectomy for pancreatic head carcinoma with portal-mesenteric venous invasion. A. prospective randomized study. Hepatogastroenterology 2004;51:427-433.
12. Fernandez-del Castillo C, Rattner DW, Warshaw AL, Standards for pancreatic resection in the 1990s. Arch Surg 1995;130:295-299; discussion 299-300.
13. Cubilla AL, Fortner J, Fitzgerald PJ: Lymph node involvement in carcinoma of the head of the pancreas area. Cancer 1978;41:880-887.
14. Ishikawa O, Ohhigashi H, Sasaki Y, et al.: Practical usefulness of lymphatic and connective tissue clearance for the carcinoma of the pancreas head. Ann Surg 1988;208:215-220.
15. Fortner JG: Regional resection of cancer of the pancreas: A new surgical approach. Surgery 1973;73:307-320.
16. Fortner JG: Recent advances in pancreatic cancer. Surg Clin North Am 1974;54:859-863.
17. Fortner JG, Kim DK, Cubilla A, et al.: Regional pancreatectomy: En bloc pancreatic, portal vein and lymph node resection. Ann Surg 1977;186:42-50.
18. Pedrazzoli S, Beger HG, Obertop H, et al.: A surgical and pathological based classification of resective treatment of pancreatic cancer. Summary of an international workshop on surgical procedures in pancreatic cancer. Dig Surg 1999;16:337-345.
19. Takahashi S, Ogata Y, Miyazaki H, et al.: Aggressive surgery for pancreatic duct cell cancer: Feasibility, validity, limitations. World J Surg 1995;19:653-659; discussion 660.
20. Reber HA, Ashley SW, McFadden D: Curative treatment for pancreatic neoplasms. Radical resection. Surg Clin North Am 1995;75:905-912.
21. Satake K, Nishiwaki H, Yokomatsu H, et al.: Surgical curability and prognosis for standard versus extended resection for T1 carcinoma of the pancreas. Surg Gynecol Obstet 1992;175:259-265.
22. Strasberg SM, Drebin JA, Linehan D: Radical antegrade modular pancreatosplenectomy. Surgery 2003;133:521-527.
23. Manabe T, Ohshio G, Baba N, et al.: Radical pancreatectomy for ductal cell carcinoma of the head of the pancreas. Cancer 1989;64:1132-1137.
24. Tsuchiya R, Oribe T, Noda T: Size of the tumor and other factors influencing prognosis of carcinoma of the head of the pancreas. Am J Gastroenterol 1985;80:459-462.
25. Hirata K, Sato T, Mukaiya M, et al.: Results of 1001 pancreatic resections for invasive ductal adenocarcinoma of the pancreas. Arch Surg 1997;132:771-776; discussion 777.
26. Ishikawa O, Ohigashi H, Sasaki Y, et al.: Practical grouping of positive lymph nodes in pancreatic head cancer treated by an extended pancreatectomy. Surgery 1997;121:244-249.
27. Nimura Y, Kato NM, Miyagawa H, et al.: Regional vs extended lymph node dissection in radical pancreaticoduodenectomy for pancreatic cancer. A. multicenter randomized controlled trial. HPB 2004;6:2.
28. Pedrazzoli S, DiCarlo V, Dionigi R, et al.: Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: A multicenter, prospective, randomized study. Lymphadenectomy Study Group. Ann Surg 1998;228:508-517.
29. Yeo CJ, Cameron JL, Lillemoe KD, et al.: Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma. Part 2. Randomized controlled trial evaluating survival, morbidity, and mortality. Ann Surg 2002;236:355-366; discussion 366-358.
30. Yeo CJ, Cameron JL, Sohn TA, et al.: Pancreaticoduodenectomy with or without extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma: Comparison of morbidity and mortality and short-term outcome. Ann Surg 1999;229:613-622; discussion 622-614.
31. Ishikawa O, Surgical technique, curability and postoperative quality of life in an extended pancreatectomy for adenocarcinoma of the pancreas. Hepatogastroenterology 1996;43:320-325.
32. Nguyen TC, Sohn TA, Cameron JL, et al.: Standard vs. radical pancreaticoduodenectomy for periampullary adenocarcinoma: A prospective, randomized trial evaluating quality of life in pancreaticoduodenectomy survivors. J Gastrointest Surg 2003;7:1-9; discussion 9-11.
33. Michalski CW, Kleeff J, Wente MN, et al.: Systematic review and meta-analysis of standard and extended lymphadenectomy in pancreaticoduodenectomy for pancreatic cancer. Br J Surg 2007;94:265-273.
34. Godart S: Lymphatic circulation of the pancreas. Bibl Anat 1965;7:410-413.
35. Waldron RL II, Luse SA, Wollowick HE, et al.: Demonstration of a retrograde pancreatic pathway: Correlation of roentgenographic and electron microscopic studies. Am J Roentgenol Radium Ther Nucl Med 1971;111:695-699.
36. Reynolds BM: Observations of subcapsular lymphatics in normal and diseased human pancreas. Ann Surg 1970;171:559-566.
37. Pissas A: Clinical and surgical anatomy studies of the lymphatic circulation of the pancreas. Bull Mem Acad R Med Belg 1990;145:351-364.
38. Pansky B: Anatomy of the pancreas. Emphasis on blood supply and lymphatic drainage. Int J Pancreatol 1990;7:101-108.
39. Ungeheuer A, Liebermann-Meffert D: [An anatomic study of the pancreatic lymphatics. Review of the summary and an abridged version of the original text]. Langenbecks Arch Chir 1990;375:303-307.
40. Hirai I, Murakami G, Kimura W, et al.: Long descending lymphatic pathway from the pancreaticoduodenal region to the para-aortic nodes: Its laterality and topographical relationship with the celiac plexus. Okajimas Folia Anat Jpn 2001;77:189-199.
41. O'Morchoe CC: Lymphatic system of the pancreas. Microsc Res Tech 1997;37:456-477.
42. Strasberg SM, Linehan DC, Hawkins WG: Radical antegrade modular pancreatosplenectomy procedure for adenocarcinoma of the body and tail of the pancreas: Ability to obtain negative tangential margins. J Am Coll Surg 2007;204:244-249.
43. Herr HW: Extent of surgery and pathology evaluation has an impact on bladder cancer outcomes after radical cystectomy. Urology 2003;61:105-108.
44. Cianchi F, Messerini L, Comin CE, et al.: Pathologic determinants of survival after resection of T3N0 (Stage IIA) colorectal cancer: Proposal for a new prognostic model. Dis Colon Rectum 2007;50:1332-1341.
45. Herr HW: Surgical factors in bladder cancer: More (nodes) + more (pathology) = less (mortality). BJU Int 2003;92:187-188.
46. Ostadi MA, Harnish JL, Stegienko S, et al.: Factors affecting the number of lymph nodes retrieved in colorectal cancer specimens. Surg Endosc 2007;21:2142-2146.
47. Jha MK, Corbett WA, Wilson RG, et al.: Variance of surgeons versus pathologists in staging of colorectal cancer. Minerva Chir 2006;61:385-391.
48. Megale Costa LJ, Soares HP, Gaspar HA, et al.: Ratio between positive lymph nodes and total dissected axillaries lymph nodes as an independent prognostic factor for disease-free survival in patients with breast cancer. Am J Clin Oncol 2004;27:304-306.
49. Voordeckers M, Vinh-Hung V, Van de Steene J, et al.: The lymph node ratio as prognostic factor in node-positive breast cancer. Radiother Oncol 2004;70:225-230.
50. van der Wal BC, Butzelaar RM, van der Meij S, et al.: Axillary lymph node ratio and total number of removed lymph nodes: Predictors of survival in stage I and II breast cancer. Eur J Surg Oncol 2002;28:481-489.
51. Herr HW: Superiority of ratio based lymph node staging for bladder cancer. J Urol 2003;169:943-945.
52. Bando E, Yonemura Y, Taniguchi K, et al.: Outcome of ratio of lymph node metastasis in gastric carcinoma. Ann Surg Oncol 2002;9:775-784.
53. Nitti D, Marchet A, Olivieri M, et al.: Ratio between metastatic and examined lymph nodes is an independent prognostic factor after D2 resection for gastric cancer: Analysis of a large European monoinstitutional experience. Ann Surg Oncol 2003;10:1077-1085.
54. Rodriguez Santiago JM, Munoz E, Marti M, et al.: Metastatic lymph node ratio as a prognostic factor in gastric cancer. Eur J Surg Oncol 2005;31:59-66.
55. Berger AC, Sigurdson ER, LeVoyer T, et al.: Colon cancer survival is associated with decreasing ratio of metastatic to examined lymph nodes. J Clin Oncol 2005;23:8706-8712.
56. Schumacher P, Dineen S, Barnett C, Jr., et al.: The metastatic lymph node ratio predicts survival in colon cancer. Am J Surg 2007;194:827-831; discussion 831-822.
57. Lee HY, Choi HJ, Park KJ, et al.: Prognostic significance of metastatic lymph node ratio in node-positive colon carcinoma. Ann Surg Oncol 2007;14:1712-1717.
58. Berger AC, Watson JC, Ross EA, et al.: The metastatic/examined lymph node ratio is an important prognostic factor after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am Surg 2004;70:235-240; discussion 240.
59. Pawlik TM, Gleisner AL, Cameron JL, et al.: Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery 2007;141:610-618.
60. Le Voyer TE, Sigurdson ER, Hanlon AL, et al.: Colon cancer survival is associated with increasing number of lymph nodes analyzed: A secondary survey of intergroup trial INT-0089. J Clin Oncol 2003;21:2912-2919.
61. Wong SL, Ji H, Hollenbeck BK, et al.: Hospital lymph node examination rates and survival after resection for colon cancer. JAMA 2007;298:2149-2154.
62. Simunovic M, Baxter NN: Lymph node counts in colon cancer surgery: Lessons for users of quality indicators. JAMA 2007;298:2194-2195.
63. Sohn TA, Yeo CJ, Cameron JL, et al.: Resected adenocarcinoma of the pancreas-616 patients: Results, outcomes, and prognostic indicators. J Gastrointest Surg 2000;4:567-579.
64. Lim JE, Chien MW, Earle CC: Prognostic factors following curative resection for pancreatic adenocarcinoma: A population-based, linked database analysis of 396 patients. Ann Surg 2003;237:74-85.
65. Schmidt CM, Powell ES, Yiannoutsos CT, et al.: Pancreaticoduodenectomy: A 20-year experience in 516 patients. Arch Surg 2004;139:718-725; discussion 725-717.
66. Tomlinson JS, Jain S, Bentrem DJ, et al.: Accuracy of staging node-negative pancreas cancer: A potential quality measure. Arch Surg 2007;142:723-767; discussion 773-764.
67. Imperato PJ, Nenner RP, Starr HA, et al.: The effects of regionalization on clinical outcomes for a high risk surgical procedure: A study of the Whipple procedure in New York State. Am J Med Qual 1996;11:193-197.
68. Ho V, Heslin MJ: Effect of hospital volume and experience on in-hospital mortality for pancreaticoduodenectomy. Ann Surg 2003;237:509-514.
69. Gordon TA, Bowman HM, Tielsch JM, et al.: Statewide regionalization of pancreaticoduodenectomy and its effect on in-hospital mortality. Ann Surg 1998;228:71-78.
70. Gouma DJ, van Geenen RC, van Gulik TM, et al.: Rates of complications and death after pancreaticoduodenectomy: Risk factors and the impact of hospital volume. Ann Surg 2000;232:786-795.
71. Lieberman MD, Kilburn H, Lindsey M, et al.: Relation of perioperative deaths to hospital volume among patients undergoing pancreatic resection for malignancy. Ann Surg 1995;222:638-645.
72. Glasgow RE, Mulvihill SJ: Hospital volume influences outcome in patients undergoing pancreatic resection for cancer. West J Med 1996;165:294-300.
73. Neoptolemos JP, Russell RC, Bramhall S, et al.: Low mortality following resection for pancreatic and periampullary tumours in 1026 patients: UK survey of specialist pancreatic units. UK Pancreatic Cancer Group. Br J Surg 1997;84:1370-1376.
74. Maa J, Gosnell JE, Gibbs VC, et al.: Exporting excellence for Whipple resection to refine the Leapfrog Initiative. J Surg Res 2007;138:189-197.
75. Riall TS, Eschbach KA, Townsend CM, Jr., et al.: Trends and disparities in regionalization of pancreatic resection. J Gastrointest Surg 2007;11:1242-1251; discussion 1251-1242.
76. Birkmeyer JD, Siewers AE, Marth NJ, et al.: Regionalization of high-risk surgery and implications for patient travel times. JAMA 2003;290:2703-2708.
77. Bilimoria KY, Bentrem DJ, Ko CY, et al.: National failure to operate on early stage pancreatic cancer. Ann Surg 2007;246:173-180.
78. Rosemurgy A, Cowgill S, Coe B, et al.: Frequency with which surgeons undertake pancreaticoduodenectomy continues to determine length of stay, hospital charges, and in-hospital mortality. J Gastrointest Surg 2008;12:442-449.
79. Kennedy EP, Yeo CJ: Pancreaticoduodenectomy with extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma. Surg Oncol Clin N Am 2007;16:157-176.
80. Pisters PW, Evans DB, Leung DH, et al.: Re: Surgery for ductal adenocarcinoma of the pancreatic head. World J Surg 2001;25:533-534.